Status:
COMPLETED
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Pain
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
- A total body weight of more than (\>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before first dose of the study drug
- Key
Exclusion
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06508762
Start Date
July 26 2024
End Date
September 10 2024
Last Update
October 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON Salt Lake City
Salt Lake City, Utah, United States, 84124